3 q13 presentation final final2
TRANSCRIPT
Third Quarter 2013 Financial Results Conference Call
October 31, 2013
2
Forward-looking StatementsForward-looking StatementsCertain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding the performance of our business, synergies, pipeline approvals, patent risk and product exclusivity, strategy, research and development, and financial guidance. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & property, plant and equipment step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, In-process research and development, impairments and other charges, ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization including intangible asset impairments and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP reconciliations can be found in our press tables under the Investor Relations tab on www.valeant.com
Note 1: The guidance in this presentation is only effective as of the date given, October 31, 2013, and will not be updated or affirmed unless and until the Company
publicly announces updated or affirmed guidance.
3
Agenda
1.Third Quarter Update
2.Bausch + Lomb Update
3.Financial Review and Guidance
4
Strong Q3 2013 Earnings and Cash Generation Performance
Excluding Impact of B+L Financing
Pre-Close
Q3 2013*
Q3 2012
2013 vs
2012Q3
2013*
2013 vs.
2012
Total Revenue $1.542 B $884 M 74%
Product Sales $1.506 B $853 M 77%
Cash Net Income $486 M $358 M 35% $498 M 39%
Cash EPS $1.43 $1.15 24% $1.51 31%
Adjusted Cash Flow $408 M $241 M 69%
* Q3 Results also reflect the impact of an earlier than expected generic entrant for Retin-A Micro of $0.04 per share
5
Revenue BreakoutBased on projected 2013 pro forma revenues
Public Pay25%75
41%
20%
18%24%*
21%
Devices
Gx/BGx
OTC / Solutions
Rx
76%
Durable Rx Products
Rx Products Subject to Patent Cliff
* 24% of Rx revenue but only 10% of total revenue
6
Limited Patent Risk
2013* 2014 2015 2016 2017
Products 1) Bromday
2) Retin-A Micro3) Wellbutrin XL (CAD)
4) Vanos
1) Atralin
2) Lotemax Suspension
3) Alrex
1) Xenazine 1) Ziana
2) Zirgan
3) Targretin
1) Lotemax Gel
2) Macugen
Total 2013
Revenue
~$250 million ~$160 million ~$150 million ~$200 million ~$50 million
% of pro forma 2013
Revenue~3.1% ~2.0% ~2.0% ~2.6% ~0.6%
* Does not include Zovirax franchise
7
U.S. Business Profile
Top 10 U.S. Products
Arestin CeraVe Dysport Elidel Lotemax PreserVision Restylane Solodyn Wellbutrin XL Xenazine
8
Q3 2013 Organic Growth
Same Store Sales Excluding Zovirax Franchise, RAM, BenzaClin
U.S. 5%
ROW Developed 1%
Total Developed Markets 4%
Total Emerging Markets 14%
Total Company 7%
Pro Forma
U.S. 5%
ROW Developed 2%
Total Developed Markets 4%
Total Emerging Markets 13%
Total Company 6%
9
Legacy Valeant - U.S.
Derm Rx Increased generic penetration impacting total U.S. branded market Most Valeant brands continue to maintain/grow market share
e.g. Elidel; Acanya; Atralin; Carac; CeraVe
Solodyn stabilized at ~$200M per year Aesthetics
Another strong quarter Continues to gain market share – particularly Dysport MVP program well received
Benefits from Mentor relationship
OraPharma continues to deliver double digit growth Neuro & Other portfolio:
Strong double digit growth in Orphan drug portfolio and Xenazine Wellbutrin XL continues to be stable at ~$150M per year Partnered products* continue to decline
* Teva and Forest generic products
10
Legacy Valeant - Emerging Markets
Central & Eastern Europe grew at 15% (same store sales) Two largest markets (Poland and Russia) continue to outpace
market growth
South East Asia/South Africa continues extremely strong growth trend Same store sales growth nearly 20%
Latin America continues to deliver double digit growth
11
Key Take Aways on Bausch + Lomb
Businesses continue to perform extremely well during integration
Synergies tracking ahead of expectations Decentralization has been embraced across the
company – especially outside the U.S. Opportunity for additional synergies in supply chain
and manufacturing Opportunity for localized business/business
development strategies
12
Key Take Aways on Bausch + Lomb Continued
As expected, R&D spend will be higher in first half of 2014 due to multiple Phase III programs reaching completion
A number of key R&D developments since announcement: Approved/Launched:
1) Peroxide Lens Cleaning Solution
2) Novel Silicone Hydrogel Monthly Disposable Contact Lens
3) Trulign Toric IOL
4) Soothe Long-lasting Dry Eye Therapy
5) PreserVision AREDS 2
6) PureVision 2 Multifocal for Presbyopia
7) BioTrueOne Day/PureVision2 Contact Lens (Japan)
8) Naturelle Contact Lens (China) Besivance patent extended to 2030
Bausch + Lomb Integration Update
14
Integration and Synergy Update
>$850 million in synergies already identified Integrated 3 global Bausch + Lomb businesses into Valeant’s
decentralized structure Synergizing corporate, global, regional and back office
functions Rationalizing R&D portfolio
Cost to achieve synergies will be approximately half of full synergies Spent ~$128M to date
IP integration on track to be completed January 1, 2014
15
Bausch + Lomb PerformanceSince Acquisition Close
Same Store Organic Growth
U.S. 15%
ROW Developed 3%
Total Developed Markets 9%
Total Emerging Markets 14%
Total Company 10%
16
How We View Our Bausch + Lomb Businesses
Description Strategy Example Markets
Businesses performing well
Accelerate U.S.; Russia; China; Turkey; Middle East; Germany
Localized strategies to accelerate growth
Turbo Charge Japan; Mexico; Brazil; South East Asia;
Canada
Reinvigorate Turn Around U.K.; Italy; Spain; Nordics; Australia; South Africa
Financial Report
18
Financial Summary
Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013
Product Sales $853M $942M $1,039M $1,064M $1,506M
Ongoing Service/Alliance Revenue $31M $44 M $29M $32M $35M
Total Revenue $884M $986M $1,068M $1,096M $1,542M
Cost of Goods Sold% (% of product sales) 23% 24% 22% 23% 27%
SG&A% (% of total revenue) 20% 20% 23% 22% 23%
R&D Expense $19M $20M $24M $24M $49M
Operating Margin (% of total revenue)
(excluding amortization) 54% 53% 52% 52% 47%
Cash EPS (Reported) $1.15 $1.22 $1.30 $1.34 $1.43
Adjusted Cash Flow from
Operations $241M $423M $345M $423M $408M
Fully Diluted Share Count 312 M 312 M 312 M 314 M 340 M
19
3Q Headwinds
Negative currency impact on revenue and profit $20m+ revenue impact $0.03 Cash EPS impact Significant new currency exposures:
Euro; Yen; Chinese Renminbi; Turkish Lira; Argentinian Peso; Indian Rupee
Bausch + Lomb pre-close interest expense and additional share count Negative impact of $0.09
Retin-A Micro generic launched August 2013 Previous guidance assumed Q1 2014 launch
Negative Cash EPS impact of $0.04 in Q3 Negative Cash EPS impact of $0.08 expected in Q4
20
Financial Guidance for 2013 as of October 31, 2013
Revenue $5.8 - $6.2 billion
$6.00 - $6.20 Adjusted Cash EPS
>$1.75 billion in Adjusted Cash Flow from Operations
Revenue $2.0 - $2.2 billion
$2.05 - $2.10 Adjusted Cash EPS
>$625 million in Adjusted Cash Flow from Operations
Revenue $5.7 - $5.9 billion
$6.11 - $6.16 Adjusted Cash EPS
>$1.8 billion in Adjusted Cash Flow from Operations
Implied Q4 2013New GuidancePrevious Guidance
See Note 1 regarding guidance
Third Quarter 2013 Financial Results Conference Call
October 31, 2013